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Running Title: Dysregulation of COPD CD8+ T cells 24 
Manuscript word count: 3499    Abstract word count: 250 25 
At a glance commentary: 26 
Scientific knowledge on the subject: Dysregulation of adaptive immunity is 27 
thought to be an important disease mechanism in COPD with increased numbers 28 
of cytotoxic T cells present in the lung. PD1 is a key regulator of T cell function 29 
and is associated with loss of cytotoxic function in the context of chronic infection 30 
and inflammation but the role of this axis in COPD and its association with T cell 31 
function is not known. 32 
What this study adds to the field: This study shows that PD1 is upregulated on 33 
T cells derived from COPD patients and that PD1 expression increases following 34 
influenza infection in an experimental lung explant tissue model. In this study 35 
CD8 T cells from COPD patients also demonstrated evidence of impaired 36 
cytotoxicity.  In contrast, infection-induced expression of the ligand PD-L1 on 37 
macrophages was diminished in COPD with associated increases in IFNγ 38 
expression. These observations provide evidence of dysregulation of T cell 39 
function in COPD through the PD1 axis, contributing to our understanding of 40 
mechanisms leading to the aberrant response to infection in COPD. 41 
This article has an online data supplement, which is accessible from this issue's 42 
table of content online at www.atsjournals.org 43 
 44 
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46 
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Abstract  47 
Rationale: COPD patients are susceptible to respiratory viral infections which 48 
cause exacerbations. Mechanisms underlying susceptibility are not understood. 49 
Effectors of the adaptive immune response; CD8+ T cells which clear viral 50 
infections, are present in increased numbers in lungs of COPD patients but fail to 51 
protect against infection and may contribute to the immunopathology of the 52 
disease. 53 
Objectives: CD8+ function and signalling through the Programmed Cell Death 54 
(PD-1) exhaustion pathway was investigated as a potential key mechanism of 55 
viral exacerbation of the COPD lung. 56 
Methods: Tissue from control or COPD patients undergoing lung resection was 57 
infected with live influenza virus ex vivo. Viral infection and expression of lung 58 
cell markers was analysed using flow cytometry. 59 
Measurements and Main Results: The proportion of lung CD8+ T cells 60 
expressing PD-1 was greater in COPD(mean=16.2%) than controls(4.4%, 61 
p=0.029).  Only epithelial cells and macrophages were infected with influenza 62 
and there was no difference in the proportion of infected cells between controls 63 
and COPD.  Infection upregulated T cell PD-1 expression in control and COPD 64 
samples.  Concurrently, influenza significantly upregulated the marker of 65 
cytotoxic degranulation (CD107a) on CD8+ T cells(p=0.03) from controls, but not 66 
from COPD patients.  Virus-induced expression of the ligand PD-L1 was 67 
decreased on COPD macrophages(p=0.04) with a corresponding increase in 68 
IFNγ release from infected COPD explants compared to controls(p=0.04). 69 
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Conclusions: This study has established a signal of cytotoxic immune 70 
dysfunction and aberrant immune regulation in the COPD lung that may explain 71 
both the susceptibility to viral infection and the excessive, inflammation 72 
associated with exacerbations. 73 
 74 
75 
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Introduction 76 
Chronic Obstructive Pulmonary disease (COPD) is an irreversible progressive 77 
disease resulting in permanent loss of lung function(1, 2). It is characterised by 78 
persistent airflow limitation and innate and adaptive immune cell infiltration into 79 
the lungs. COPD patients experience recurrent viral infections accompanied with 80 
lung inflammation resulting in exacerbations which are characterised by a 81 
sudden decline in lung function, often require hospitalisation, and may result in 82 
death(3-5). CD8+ T cells, which play a key role in anti-viral immunity have been 83 
shown to be present in greater numbers in the lungs of patients with more severe 84 
COPD as measured by FEV1(6) but these patients remain at great risk from the 85 
impacts of respiratory viral infection.  86 
Recent studies have suggested that regulation of T cell function can occur 87 
via the T cell exhaustion pathway in response to viral infection(7). PD-L1 is the 88 
ligand for the Programmed Cell Death protein 1 (PD-1), which is a member of the 89 
CD28 family of T cell receptors. The canonical pathway of T cell activation is via 90 
antigen presentation in the context of MHC to elicit T cell receptor (TCR) 91 
activation, co-stimulation of CD28 provides a necessary signal to prevent T cell 92 
anergy(8). Contrastingly, PD-L1 binding to PD-1 causes inhibition of T cell 93 
proliferation and cytokine release(9). T cell exhaustion is a state of T cell 94 
dysfunction normally associated with chronic viral infection and cancer and is 95 
associated with prolonged stimulation of T cells due to persistent antigen 96 
presentation.  However recent work has suggested that expression of PD-1 is 97 
also closely linked to T cell differentiation and can be expressed on acutely 98 
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activated T cells but usually subsides during resolution of infection (10).  The PD-99 
1 pathway has recently been suggested as potentially relevant in COPD 100 
pathogenesis, as the presence of PD-1+ T effector cells in the blood correlated 101 
with disease severity(10). Kalathil et al. detected PD-1 expression in a population 102 
of blood CD4+CD127+ T cells, although there was no evidence of functional 103 
exhaustion(10). The potential for T lymphocytes to express an exhausted 104 
phenotype in the COPD lung has not yet been established. We hypothesised that 105 
T cells in the COPD lung would express an exhausted phenotype compared to 106 
cells derived from control lungs and that T cell exhaustion may account for poor 107 
responses to viral infection that may lead to COPD exacerbations.   108 
 109 
 110 
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Materials & Methods 111 
Ex vivo infection of lung parenchymal tissue 112 
Resected human lung tissue was obtained from consented patients undergoing 113 
airway re-section surgery at our regional thoracic surgical unit. The collection of 114 
tissue was approved by and performed in accordance with the ethical standards 115 
of the Southampton and South West Hampshire Research Ethics Committee, 116 
LREC no: 09/H0504/109. Ex-smokers were defined as individuals who had quit 117 
smoking for >6 months. Parenchymal tissue, distant from the resection margin 118 
and any gross pathology was dissected from the lobe.  Tissue was cut into 1mm3 119 
sections and added to a 24-well flat-bottomed culture plate before washing with 120 
Dulbecco’s Phosphate Buffered Saline (DPBS – Sigma, Poole, UK). Washing of 121 
the tissue was performed by removing DPBS from the wells and replacing it with 122 
fresh DPBS, followed by unsupplemented RPMI and finally RPMI supplemented 123 
with 1% penicillin/streptomycin (both Life Technologies, Paisley, UK) and 1% 124 
gentamycin (GE Healthcare, Little Chalfont, UK). Tissue was then incubated 125 
overnight at 37ºC and 5% CO2.  Ex vivo infection of resected lung tissue with 126 
H3N2 X31 influenza virus (a kind gift of 3VBiosciences) was then carried out as 127 
previously described(11).  128 
 129 
T cell and Monocyte Isolation & differentiation  130 
CD8+ T cells and Monocytes were isolated from human peripheral blood 131 
mononuclear cells (PBMC) using MACS technology (Miltenyi Biotec, Bisley, UK) 132 
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and monocytes differentiated into macrophages by culturing for 12 days with 2 133 
ng/ml GM-CSF.  134 
 135 
Flow cytometry analysis 136 
Samples were resuspended in FACS buffer (PBS, 0.5% w/v BSA, 2 mM EDTA) 137 
containing 200 µg/ml human IgG before being incubated on ice in the dark for 30 138 
min in the presence of fluorescently-labelled antibodies as previously 139 
described(11). Flow cytometric analysis was performed on a FACSAria using 140 
FACSDiva software v5.0.3 (BD Biosciences, Oxford, UK).   141 
 142 
RNA Isolation & RT-PCR 143 
RNA was extracted from 25,000 flow cytometry sorted CD4+ or CD8+ lung T 144 
cells using a Stratagene Nanoprep Kit (Agilent Technologies, Stockport UK).  145 
Reverse transcription was carried out using a High Capacity cDNA Reverse 146 
Transcription Kit (Life Technologies) with random hexamers carried out 147 
according to the manufacturer’s protocols. TIM3 gene expression was analysed 148 
using TaqMan universal PCR master mix, No AmpErase® UNG in a 7900HT fast 149 
real-time PCR system instrument (all Life Technologies). Gene expression was 150 
normalized to β2-microglobulin gene expression and quantified using the ∆∆ CT 151 
method. 152 
 153 
Supernatant analyses 154 
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IFNγ concentrations in culture supernatants were analysed by Luminex assay as 155 
per manufacturer’s instructions (Bio-Rad, Hemel Hempstead, UK).   156 
 157 
ELISpot 158 
ELISpot for Human IFN-γ (MabTech, Stockholm, Sweden) was performed using 159 
0.45 µm MultiScreen-IP Filter Plates (Millipore, Watford, UK) as previously 160 
described(11). Briefly, MDMs were either not infected, or were treated with 2.5 x 161 
104 pfu/ml X31 Influenza A H3N2 virus at 37ºC for 2 h before washing and were 162 
then added to each well at a concentration of 5 x 104 cells/well and 2.5 x 105 163 
monocyte-depleted PBMC or 1 x 105 CD8+ T cells were added to MDM-164 
containing wells and incubated at 37ºC for a further 22 h. 165 
 166 
Statistics 167 
Analysis of two groups was performed using Wilcoxon’s signed rank test for 168 
paired data and a Mann-Whitney U test for unpaired data. Chi-squared test and 169 
Fishers exact test were used for categorical data (GraphPad Prism v6, GraphPad 170 
Software Inc., San Diego, USA).  Results were considered significant if p<0.05.  171 
 172 
For full details of all methods please see supplemental data 173 
174 
Page 9 of 56  AJRCCM Articles in Press. Published on 30-October-2015 as 10.1164/rccm.201504-0782OC 
 Copyright © 2015 by the American Thoracic Society 
McKendry page 10 
 
 10
Results 175 
Patients 176 
The clinical characteristics of surgical patients are presented in Table 1. COPD 177 
patients were matched with controls for age, but had a greater smoking history 178 
and lower FEV1% predicted and greater airflow obstruction. 179 
 180 
Lung resident T cell phenotype in COPD 181 
Previous studies have demonstrated an increase in CD8+ T cells in the COPD 182 
lung by immunohistochemistry (6, 12). To validate our flow cytometry method we 183 
measured the proportion of CD4+ and CD8+ T cells disaggregated from the 184 
explanted lung tissue using the gating strategy outlined in Figure 1A. The 185 
proportion of CD4+ T cells was significantly lower in COPD (mean=39.3%) than 186 
controls (mean=47.3%), p=0.016 (Figure 1B). Conversely, the proportion of 187 
CD8+ T cells was greater in COPD (mean=42.7%) than controls (31.2%), 188 
p=0.004 (Figure 1C & Supplementary Data Figure E1A+B).  Moreover the 189 
majority of these cells were effector memory cells (CCR7-), suggesting we are 190 
studying lung resident cells and not carry over from the blood compartment 191 
(Supplementary Data Figure E2).  192 
 193 
Patients with COPD exhibit elevated proportions of PD1+ T cells 194 
To investigate if the immune defect in CD8+ T cells in COPD was associated with 195 
markers of exhaustion, PD-1 expression by lung resident T cells was quantified 196 
in control and COPD patients (Figure 2). The mean proportion of CD4+ T cells 197 
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from controls that expressed PD-1 was 1.68%, compared to a mean of 4.51% in 198 
COPD tissue (Figure 2A - p=0.07). A mean of 4.39% of CD8+ T cells from control 199 
lung tissue expressed PD-1, while a mean of 16.24% expressed PD-1 in COPD 200 
tissue (Figure 2B - p=0.0291). There was therefore evidence of a greater 201 
proportion of T cells expressing PD-1 in COPD lungs compared to control tissue. 202 
 The co-expression of PD-1 and TIM-3 has been used to identify 203 
functionally exhausted T cells in murine models(13). In contrast to PD-1, T cells 204 
isolated from tissue of either controls (n=9) or COPD individuals (n=12) did not 205 
express detectable surface TIM-3. To ensure that lack of TIM-3 detection was not 206 
due to an effect of collagenase on the lung T cells, RT-PCR experiments were 207 
performed using CD4+ and CD8+ T cells sorted from lung parenchyma. TIM-3 208 
mRNA was not detected in either CD4+ or CD8+ T cell samples from controls or 209 
COPD patients (Supplementary Data Figure E3). 210 
 211 
Influenza infection of lung explants 212 
In order to assess the functional consequences of a viral infection on the 213 
activation of T cells, we utilised a previously validated ex vivo model of lung 214 
explant infection (11, 14, 15). In that previous study, H3N2 X31 influenza A was 215 
shown to infect epithelial cells and macrophages in both human bronchial and 216 
parenchymal tissues (11, 15). Endothelium, fibroblasts, B cells and T cells were 217 
not infected by X31(14). Therefore infection of epithelial cells and macrophages 218 
was quantified using the gating strategy outlined in Figure 3A using the 219 
expression of the influenza protein NP-1. Epithelial cells and macrophages from 220 
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inactivated (UV treated) tissue did not express NP-1. A mean of 10.38% of 221 
epithelial cells from control patients expressed NP-1 (Figure 3B) compared to 222 
9.19% form COPD samples (p=0.77). There were also no significant difference 223 
(p=0.50) between the proportion of macrophages infected with virus from control 224 
(mean 18.12%) or COPD tissue (mean 14.45%) (Figure 3C).  225 
 226 
T cell responses to influenza infection of lung explants 227 
As there was no difference in the proportion of virally infected cells between 228 
healthy and COPD subjects, these data suggest that the mechanisms leading to 229 
COPD exacerbations may arise as a failure to adequately control the immune 230 
response rather than due to an increased level of infection. PD-1 expression was 231 
therefore measured to investigate differential immune responses to infection. 232 
Figure 4 shows that PD-1 is upregulated on CD4+ and CD8+ T cells in both 233 
control and COPD explants in response to X31 infection (Fig 4A & 4B). CD8+ 234 
PD-1 expression in controls increased from a mean sMFI of 165.1 to 237.7 in 235 
X31 samples (p=0.01). Ex vivo CD8+ T cells from COPD patients express a 236 
mean sMFI PD-1 of 231 which increased to 287.7 with X31 treatment (p=0.02). A 237 
similar pattern of expression in response to infection was seen for CD4+ T cells. 238 
Live virus induced a significantly greater fold increase (median 1.37-fold) in PD-1 239 
expression on COPD CD8+ (p=0.0134), but not CD4+ (p=0.2847), T cells than 240 
UV-irradiated virus (Supplementary Data Figure E4C&D).  The percentage of 241 
CD8+ T cells from both controls and COPD patients expressing PD-1 was also 242 
increased in response to X31 treatment.  There was also a significant increase in 243 
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the proportion of CD4+ T cell PD-1 expression from COPD patients but not 244 
controls in response to infection (Supplementary Data Figure E4A&B).  PD-1 is 245 
upregulated during X31 infection, but the fold increase in expression induced by 246 
influenza in CD4+ (p=0.31) and CD8+ (p=0.27) T cells did not differ between 247 
control and COPD samples (Supplementary Data Figure E4E&F). 248 
To analyse the functional relevance of this PD-1 upregulation, we 249 
assessed the expression of the degranulation marker CD107a in response to 250 
viral infection between controls and COPD individuals (Figure 4C&D). CD4+ T 251 
cells from both control and COPD samples significantly upregulated CD107a in 252 
response to infection (p=0.03) (Figure 4C).  In contrast, whilst CD8 T cells from 253 
controls significantly upregulated (p=0.03) CD107a in response to viral infection 254 
there was not a significant upregulation by CD8 cells derived from COPD 255 
explants (Figure 4D).  Taken together these results suggest that CD8 T cells in 256 
the COPD lung may have an impaired degranulation response to viral infection. 257 
 258 
Lung macrophage expression of PD-L1 is compromised in COPD 259 
T cells downregulate their effector functions due to ligation of PD-1 by PD-L1. To 260 
assess whether there was dysregulation of PD-L1 in our ex vivo model, we also 261 
measured the expression of this ligand on alveolar epithelial cells and 262 
macrophages (Figure 5) and to elucidate whether PD-L1 expression 263 
corresponded to viral infection and T cell upregulation of PD-1. The results 264 
indicated that epithelial cells express PD-L1 in human parenchyma, but its 265 
expression is lower (NI pooled sMFI = 142) than in macrophages (NI pooled 266 
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sMFI = 442.47) and is not regulated by acute X31 infection (Supplementary Data 267 
Figure E5).  Macrophages, however, upregulate PD-L1 in response to infection in 268 
control samples (p=0.02) and COPD samples (p=0.02) (Figure 5A). Intriguingly, 269 
we observed lower expression of PD-L1 in COPD in response to infection 270 
compared to infected control samples (p = 0.04) Figure 5B).  271 
 As PD-L1 has been previously shown to be directly responsible for 272 
reducing CD8 T cell function in response to influenza (7), these data suggest that 273 
COPD macrophages may be unable to adequately modulate T cell activation.  To 274 
assess this in the explant model we analysed the release of IFNγ into 275 
supernatants from tissue infected with X31 for 24 h (Figure 5C).  Infection with 276 
influenza caused significant IFNγ release from both control (p=0.02) and COPD 277 
(p=0.004) explants (Figure 5C).  However COPD explants produced significantly 278 
more IFNγ in response to influenza (mean 86 pg/ml) than infected control 279 
explants (mean 49 pg/ml, p=0.04) (Figure 5D), suggesting that the decrease in 280 
PD-L1 expression by infected macrophages does have a functional effect on T 281 
cell cytokine release. 282 
 283 
Fluticasone does not affect CD8+ T cell PD-1 expression 284 
In order to ensure that the effects we were seeing were not an epiphenomenon 285 
due to inhaled corticosteroid use by COPD patients, we incubated peripheral 286 
blood derived CD8+ T cells with 10-7 M fluticasone propionate (FP) for 24 h and 287 
analysed cell surface PD-1 expression by flow cytometry (Figure 6A).  There was 288 
no significant upregulation of PD-1 on CD8+ T cells in response to fluticasone.   289 
290 
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Discussion 291 
In the present study, we have demonstrated evidence of dysregulation of T cell 292 
immune function in the COPD lung. We have shown that a greater proportion of 293 
T cells express PD-1 in COPD tissue than in controls, but that this signal is not 294 
one of the canonical fully exhausted phenotype as there was no co-expression of 295 
TIM-3 at either the mRNA or protein level.  However this finding was associated 296 
with evidence of diminished T cell cytotoxic degranulation responses to viral 297 
infection. Study of the virus-induced expression of the exhaustion ligand PD-L1 298 
demonstrated that it is decreased on COPD macrophages with a corresponding 299 
increase in IFNγ release into supernatants from virally infected lung explants. 300 
These data are complex to interpret but reflect the complex regulation of T cells 301 
in the lung and interactions with the disease effects of COPD. The findings 302 
highlight that T cell regulation, of which exhaustion is an important component, is 303 
impacted upon by both aberrant T cell functionality and loss of regulatory control 304 
in the context of COPD. The consequences of these phenomena may explain the 305 
complex relationship between viral susceptibility and excessive inflammation 306 
which is the hallmark of acute exacerbations.  307 
 The increased proportion of CD8+ T cells in the lung parenchyma of 308 
COPD patients has been described and it is postulated that this may be due to 309 
their anti-viral properties(16, 17). As CD8+ T cells elicit potent anti-viral 310 
responses(18), the raised proportions of activated CD8+ T lymphocytes in COPD 311 
lungs may indicate a response to increased frequency of infection (19, 20). The 312 
localisation of T cells in a murine model of viral infection during RSV or Influenza 313 
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A virus infection resulted in recruitment of CD8+ T cells to the lungs, with virus 314 
specific T cells residing in the lungs for 30 days, with the majority of IFNγ-315 
secreting CD8+ cells being found in lung tissues rather than in the periphery(21). 316 
Purwar et al.(22) have shown that human lung contains resident memory T cells 317 
(TRM) cells independently of challenge, and these cells can secrete potent 318 
inflammatory mediators upon stimulation, underlining the importance of TRM in 319 
protecting the host during infection. Recently other work using in vitro stimulation 320 
of lung derived T cells has demonstrated evidence of dysfunction in COPD. 321 
CD4+ T cells particularly in advanced disease demonstrated aberrant 322 
polarization patterns but features of exhaustion or response to direct viral 323 
infection were not explored (23). 324 
 PD-1-expressing lymphocyte populations were identified in lung 325 
parenchyma, with a greater proportion of T cells expressing this marker in 326 
patients with COPD.  This expression was significantly upregulated by CD4+ and 327 
CD8+ T cells in response to infection. The inducible nature of PD-1 in response 328 
to activation was first identified by Agata et al.(24) and this previous work agrees 329 
with the findings presented above. PD-1 is a marker of T cell exhaustion, but it is 330 
also expressed by activated T cells which appear to be fully or partly functional 331 
(25, 26). PD-1 is upregulated by T lymphocytes in acute models of LCMV, but 332 
these are resolved before T cells display an exhausted phenotype(27).  However, 333 
acute infection in the human ex vivo model appears to yield similar results to 334 
those of the previously reported in vivo murine model of influenza infection(28).   335 
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 The release of granzyme B and perforin is utilised by CD8+ T cells to 336 
induce apoptosis of virally-infected cells(29). Intracellular staining of these 337 
proteins was not performed due to variable levels of Granzyme B detection in 338 
unstimulated samples, but CD107a can be used as a surrogate marker for T cell 339 
cytotoxic degranulation(29). CD107a was upregulated by CD4 and CD8 T cells in 340 
controls but not COPD in response to influenza infection.  An inability to produce 341 
cytotoxic proteins in response to viral infection infers an associated host 342 
susceptibility to infection and potentially a failure to clear the pathogen resulting 343 
in prolongation of clinical illness seen in COPD.  In combination with the 344 
increased PD-1 expression in COPD, these data are consistent with the 345 
hierarchical loss of T cell function characteristic of T cell exhaustion(30).  These 346 
observations suggest that there are an increased proportion of CD8+PD-1+ T 347 
cells in the COPD lung that are activated but carry important functional features 348 
of exhaustion that have an impaired ability to release cytotoxic granules. 349 
 Cytotoxic responses are predominantly associated with CD8 T cell and NK 350 
cells, but in this model CD107a was also upregulated by CD4 T cells. This finding 351 
adds to the growing literature of cytotoxic CD4 T cells in viral infection(31, 32), 352 
including influenza(33). It is unclear as to whether cytotoxic CD4+ T cells are a 353 
unique subset of T cells, or whether their killing ability is induced during an 354 
impaired CD8 response in the context of COPD and this requires further study.   355 
 Previous investigation into PD-L1 regulation of T cell responses to 356 
respiratory viruses has focussed on expression by epithelial cells(7, 34, 35). 357 
Influenza viral infection of control and COPD tissue did not modulate PD-L1 358 
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expression by epithelial cells, even though it was constitutively expressed at a 359 
very low level (Supplementary Figure E5). Although there was no difference in 360 
the basal expression of this ligand between controls and COPD, macrophages 361 
expressed significantly more PD-L1 in response to infection in both groups. Our 362 
previous data indicate that this PD-L1 upregulation is functionally relevant, as 363 
use of a PD-L1 blocking antibody in our influenza–infected MDM model 364 
increased production of IFNγ by autologous CD8 T cells, implicating PD-L1 in the 365 
regulation of anti-viral cytokine release(11). In the current study, infected COPD 366 
macrophages expressed significantly less PD-L1 than control macrophages, 367 
which in turn correlated with an increase in IFNγ release from infected COPD 368 
lung.   Thus not only does there appear to be a defect in the antiviral cytotoxic 369 
function of T cells in COPD but also an inability to arrest the activation of these T 370 
cells by decreased PD-L1 expression. These findings are consistent with well 371 
recognised clinical phenomena of increased severity of virally infection, 372 
prolonged viral shedding and structural lung damage associated with 373 
exacerbations.  374 
 Our previous study suggested that autocrine IFNβ production by alveolar 375 
macrophages was a driver of PD-L1 expression(11). Rhinovirus-driven asthma 376 
exacerbations have been postulated to be a direct result of deficient IFNβ 377 
production by bronchial epithelial cells from asthmatics for the last decade(36).  378 
More recent work challenging COPD patients with rhinovirus to mimic an 379 
exacerbation suggests a similar defect in IFNβ production may also operate in 380 
COPD(37).  Unfortunately, we are unable to directly measure IFNβ production in 381 
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virally-challenged lung explants and so deficient production of this cytokine 382 
leading to a reduced expression of PD-L1 in response to virus in COPD remains 383 
an intriguing possibility.  384 
 This work has been performed using whole lung explants from patients 385 
undergoing thoracic surgery. This approach permits the analysis of the complex 386 
interactions between structural and immune cells and the impact of viral infection 387 
in this complex composite system. This validated model has contributed to our 388 
understanding of cellular immunity in the human lung with a clinically relevant 389 
pathogen (live influenza virus) which would be not feasible in vivo, but it has 390 
limitations when studying immune responses which should be considered. Firstly 391 
lung explants are isolated from the effects of immune cells trafficking from the 392 
blood and so these conclusions are valid for lung resident cells only. We feel 393 
however that, as exhaustion signalling is confined to impacting on terminally 394 
differentiated T cells, it remains a very valid model in this context. Furthermore 395 
patients donating tissue were undergoing surgery for indications including lung 396 
cancer which may impact on the findings. However only tissue distant to the 397 
tumour site was used and the COPD related effects on immunity were apparent 398 
whilst the co-morbidities leading to surgery were present in both COPD and 399 
controls. In using lung derived T cells we have been limited in the number of cells 400 
available for phenotypic analysis and hence the breadth of phenotypic markers 401 
was also constrained to a single flow cytometry panel. We have used established 402 
markers to identify T cells and their function. Cytotoxic function can be measured 403 
in a number of ways including expression of perforin and granzyme B as well as 404 
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the marker CD107a. This latter marker has been well established as a signature 405 
of cytotoxic degranulation(7, 38). However to fully understand the dysfunctional 406 
nature of T cells further studies exploring functional killing ability and the antigen 407 
specific nature of dysfunctional T cell subsets are required. In addition the 408 
interaction with functional readouts of T cells and the response to infection with 409 
treatments such as inhaled corticosteroids and also active smoking requires 410 
further study to provide insights into how these may diminish protective immunity. 411 
 Taken together, these data indicate a dysregulation of CD8+ T cell 412 
responses to viral infection in the COPD lung.  Moreover, they suggest that viral 413 
exacerbations of COPD may arise due to a combination of an already active CD8 414 
T cell population with an impaired anti-viral action coupled with an inability to 415 
down-regulate cytokine release from these as a result of deficient PD-L1 416 
expression. However interpretation of the observed results requires caution as it 417 
is possible that reduction of PD-L1 expression enables increased IFNγ 418 
expression which aids viral clearance in the diseased lung. Whichever the 419 
direction of effect in vivo, these observations have important potential 420 
implications for the therapeutic manipulation of T cell function including the use of 421 
PD-1 and PD-L1 blocking antibodies to modulate T cell activity which are in use 422 
as cancer therapies today. Further studies are required to investigate the 423 
translational potential of this approach. If this axis is modulated imprecisely, risks 424 
to the patient of pneumonitis, are already recognised(39).  The key question 425 
remains as to what drives the increased expression of PD-1 in the COPD airway 426 
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and whether cells manifesting this functional phenotype are the ones specific to 427 
pathogens or autoantigens that play a key role in the pathogenesis of COPD. 428 
429 
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 430 
 Control COPD p Value 
N 24 33 - 
Age (years) 
70.5 
(61 – 76) 
67 
(60.5 – 74) 
0.75# 
Gender M/F 12 / 12 16 / 17 0.91† 
BMI 
27.25 
(22.63 – 31.55) 
23.7 
(21.25 – 28.95) 
0.23# 
Confirmed 
corticosteroid use 
1 9 0.0336‡ 
Smoker 
(Never/Ex/Current) 
6 / 15 / 3 1 / 20 / 12  0.0671‡ 
Pack Years 
21 
(.625 – 52.5) 
40 
(31.25 – 62.5) 
0.025# 
FEV1% 
98 
(91.9 – 112) 
76.13 
(67 – 86) 
< 0.0001# 
FEV1/FVC ratio 
0.776 
(0.73 – 0.805) 
0.601 
(0.551 – 0.654) 
< 0.0001# 
Table 1: Clinical characteristics of surgical patients. Data are presented as 431 
median and IQR shown. Ex-smokers were defined as individuals who had 432 
stopped smoking for > 6 months prior to surgery. BMI data shown represents 16 433 
Control and 17 COPD patients. #Mann Whitney U Test, †Chi-squared test, ‡ 434 
Fishers Exact test.  Co-morbidity data can be viewed in Supplementary Table E3. 435 
 436 
 437 
438 
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Figure Legends 592 
 593 
Figure 1. Flow cytometry gating strategy for T cells in lung parenchymal 594 
tissue. After resting explanted lung tissue overnight, tissue was digested with 595 
collagenase and cells analysed by flow cytometry (A) Unstained singlet 596 
population was obtained from digested tissue. Dead cells were excluded using 597 
LIVE/DEAD® Fixable Aqua Dead Cell Stain. Live singlet CD45+ population was 598 
then identified and from this a CD45+CD3+ T cell population. The CD45+CD3+ T 599 
cell population was divided into CD4+ and CD8+ T cells. (A) Proportion of CD4+ 600 
(B) and CD8+ T cells are gated on the live CD45+CD3+ population. Control n = 601 
20, COPD n = 24. Median and IQR shown. Data analysed using a Mann-Whitney 602 
U-test # p<0.05, ## p<0.01. 603 
 604 
Figure 2. Intrinsic PD-1 expression by CD4 and CD8 T cells in controls and 605 
COPD. After resting explanted lung tissue overnight, tissue was digested with 606 
collagenase and cells analysed by flow cytometry. T cells are gated on the live 607 
CD45+CD3+ population. (A) Proportion of CD4+ (B) and CD8+ T cells 608 
expressing surface PD-1. Control n = 9, COPD n = 12. Median and IQR shown. 609 
Data analysed using a Mann-Whitney U-test # p<0.05. Note that y axis limit is 610 
changed from 15% to 50% between (A) and (B). 611 
 612 
Figure 3. Infection of Epithelial cells and Macrophages from lung 613 
parenchymal tissue. After resting explanted lung tissue overnight, 1 x 106 pfu/ml 614 
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H3N2 X31 influenza virus or a UV-irradiated aliquot of virus (UVX31) was added 615 
for 2 h. After washing, media was replaced and the tissue was incubated for a 616 
further 22 h followed by collagenase digestion and flow cytometry analysis (A) 617 
Epithelial cells were identified as CD45- EpCAM+ cells. Macrophages were 618 
identified as CD45+ HLA-DR+ cells. (B) Proportion of Epithelial cells and (C) 619 
Macrophages expressing NP-1 after treatment with 1x106 pfu/ml live X31 virus 620 
(X31), UV-irradiated virus (UVX31) or non-infected (NI). NP-1+ cells were 621 
classified as infected by the influenza virus. Median and IQR shown. Data 622 
analysed using Wilcoxon’s signed rank test (** p<0.01, *** p<0.001) to analyse 623 
intra group variations and Mann-Whitney U-test to analyse intergroup variations. 624 
(n.s. = not significant)  625 
 626 
Figure 4. Expression of PD-1 and CD107a by T cells in response to tissue 627 
infection by X31 influenza. (A) CD4+ (B) and CD8+ T cell expression of PD-1 628 
was quantified by flow cytometry in non-infected (NI), live X31 virus infection 629 
(X31) and UV-irradiated virus (UVX31) lung samples. Control n = 9, COPD n = 630 
12. (C) CD4+ (D) and CD8+ T cells expression of CD107a was also quantified by 631 
flow cytometry. Control n = 6, COPD n = 6. Median and IQR shown. Data 632 
analysed using a Wilcoxon-signed rank test (* p<0.05, ** p<0.01) and Mann-633 
Whitney U-test to analyse intergroup variations. 634 
 635 
Figure 5. Expression of PD-L1 by Macrophages and IFNγ production in 636 
response to tissue infection by X31 influenza. (A) Expression of PD-L1 by 637 
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Macrophages was measured in non-infected (NI), live X31 virus infection (X31) 638 
and UV-irradiated virus (UVX31) samples. (B) Differences in PD-L1 expression 639 
between X31 control and X31 COPD samples. Control n = 9, COPD n = 11. (C) 640 
IFNγ was measured from supernatants of non-infected (NI), live X31 virus 641 
infection (X31) and UV-irradiated virus (UVX31) explant tissue. (D) Differences in 642 
IFNγ production between X31 control and X31 COPD samples. Control n = 10, 643 
COPD n = 8. Median and IQR are shown. Data in (A) & (C) were analysed using 644 
a Wilcoxon-signed rank test * p<0.05, ** p<0.01.  Data in (B) & (D) were analysed 645 
using a Mann-Whitney U test # p<0.05, ## p<0.01. 646 
 647 
Figure 6. Effect of Fluticasone Propionate on blood CD8+ T cell PD1 648 
expression PD-1 expression was measured in non-infected blood CD8 T cells 649 
incubated in the presence or absence of 10-7M FP by flow cytometry (n=4). 650 
Median and IQR are shown. Data were analysed using a Wilcoxon-signed rank 651 
test. 652 
 653 
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Methods  9 
Ex vivo infection of resected human lung tissue 10 
Lung tissue was obtained from patients undergoing airway re-sectioning surgery at 11 
Southampton General Hospital. The collection of tissues was approved by and 12 
performed in accordance with the ethical standards of the Southampton and South 13 
West Hampshire Research Ethics Committee, LREC no: 09/H0504/109. 14 
Parenchymal tissue, distant from the resection margin and any gross pathology was 15 
dissected from the lobe.  Tissue was cut into 1mm3 sections and added to a 24-well 16 
flat-bottomed culture plate before washing with DPBS (Sigma, Poole, UK). Washing 17 
of the tissue was performed by removing DPBS from the wells and replacing it with 18 
fresh DPBS, followed by unsupplemented RPMI and finally RPMI supplemented with 19 
1% penicillin/streptomycin ((both Life Technologies, Paisley, UK) and 1% 20 
gentamycin (GE Healthcare, Little Chalfont, UK). Tissue was then incubated 21 
overnight at 37ºC and 5% CO2.  22 
Tissue was infected and analysed according to according to the method 23 
described by Staples et al(1). After resting overnight the media was replaced with 24 
serum-free RPMI supplemented with 100 U/ml penicillin, 100 µg/ml streptomycin, 2 25 
mM L-glutamine and 250 ng/ml fungizone.  Influenza A virus strain X31 was supplied 26 
at a concentration of 4 x 107 pfu/ml (a kind gift of 3VBiosciences).  Inactivated virus 27 
(UVX31) was prepared by exposure of the X31 to an ultra-violet (UV) light source for 28 
2 h.  X31 or UVX31 at a concentration of 1 x 106 pfu/ml was added to designated 29 
wells, with control non-infected wells. Tissue was incubated at 37ºC and 5% CO2 for 30 
2 h to allow for infection of cells residing in the tissue. Supernatant was removed and 31 
tissue was washed three times with unsupplemented RPMI in order to remove 32 
excess virus from the wells. Serum-free RPMI supplemented with 100 U/ml penicillin, 33 
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100 µg/ml streptomycin, 2 mM L-glutamine and 250 ng/ml fungizone was added to 34 
the wells and tissue was incubated at 37ºC and 5% CO2 for a further 22 h. 35 
Protocol used to digest tissue was adapted from Holt et al (2). Briefly, Tissue 36 
was added to a solution of pre-warmed unsupplemented RPMI and 0.5 mg/ml 37 
collagenase type I (Sigma) for digestion. A magnetic stirrer was added to the solution 38 
in order to mechanically disaggregate tissue. Collagenase digestion occurred at 39 
37ºC for 15 min. This tissue digestion protocol was optimised using blood-derived 40 
cells to ensure there was no effect on the major T cell markers expressed on naive 41 
blood cells.  After digestion the solution was filtered through a 35 µm pore straining 42 
cap into 5 ml round-bottomed polypropylene FACS tubes (BD Biosciences) in 43 
preparation for FACS analysis. 44 
 45 
Monocyte Isolation & differentiation  46 
Human peripheral blood mononuclear cells (PBMC) were isolated from heparinised 47 
blood by centrifugation on Ficoll-Paque® (GE Healthcare, Little Chalfont, UK).  48 
Monocytes were then isolated from the PBMC using CD14+ microbeads (Miltenyi-49 
Biotec, Bisley, UK) according to the manufacturer’s instructions.  Isolated monocytes 50 
were resuspended in complete RPMI supplemented with 2 ng/ml GM-CSF (R&D 51 
Systems, Abingdon, UK).  MDM were then washed extensively with basal RPMI 52 
before addition of virus RS-RPMI.  Collection of samples for this part of the study 53 
was approved by the Southampton and South West Hampshire Research Ethics 54 
Committee (reference: 08/H0504/138).  CD8+ T cells were isolated from the 55 
monocyte-depleted PBMC that resulted from this separation step using CD8+ 56 
microbeads (Miltenyi-Biotec) before freezing at -80°C in 10% (v/v) DMSO/HI-FBS for 57 
use in later ELISpot analysis. 58 
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 59 
Infection of lung macrophages and MDM 60 
Influenza A virus strain X31 was supplied at a concentration of 4 x 107 pfu/ml (a kind 61 
gift of 3VBiosciences).  Inactivated virus (UVX31) was prepared by exposure of the 62 
X31 to an ultra-violet (UV) light source for 2 h.  Macrophages were incubated for 2 h 63 
with no virus, or 4000 pfu (lung) or 500 pfu (MDM) of X31 or UVX31.  Supernatants 64 
were harvested (T-2), the cells washed three times, the final wash was harvested 65 
(T0) and fresh RS media was added to the MDMs.  Cells were then washed and 66 
incubated for a further 22 h at 37°C, 5% CO2. After a further 22 h, supernatants were 67 
harvested (T22) for cytokine analysis and cells collected and immediately analysed 68 
by flow cytometry.  For phenotypic characterisation of influenza infected 69 
macrophages, cells were removed from culture plates using a non-enzymatic cell 70 
dissociation solution (Sigma).   71 
 72 
Flow cytometry analysis 73 
Samples were resuspended in FACS buffer (PBS, 0.5% w/v BSA, 2 mM EDTA) 74 
containing 200 µg/ml human IgG (Sigma).  75 
Lung explants:  76 
Single cell suspensions derived from collagenase digestion were incubated on ice in 77 
the dark for 30 min with the following antibodies: Phycoerythrin-CF594 (PE-CF-594)-78 
conjugated anti-CD45, Peridinin-Chlorophyll Protein-Cyanine 5.5 (PerCPCy-5.5)-79 
conjugated anti-EpCAM-1 (CD326), and Allophycocyanin-Cyanine 7 (APC-Cy7)-80 
conjugated anti-HLA-DR, Phycoerythrin (PE)-conjugated anti-PD-L1, PE-Cy7 81 
conjugated anti-CD3, PerCPCy5.5-conjugated anti-CD4 and APC-Cy7-conjugated 82 
anti-CD8 (All BD Biosciences, Oxford, UK). Appropriate isotype and fluorescence-83 
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matched control antibodies were added in a sample of the cells to aid gating of cell 84 
populations. After washing, intracellular staining for viral nucleoprotein (NP)-1, was 85 
performed using BD Cytofix/Cytoperm kit according to manufacturer’s instructions, 86 
and AlexaFluor 488 (AF488)-conjugated anti-NP1 antibody (HB-65, a kind gift of 87 
3VBiosciences).  The gating strategy is shown in Figure 1A. 88 
MDMs & blood T cells:  89 
Isolated macrophages were incubated on ice in the dark for 30 min with the following 90 
antibodies: PE-conjugated anti-PD-L1, Allophycocyanin (BD Biosciences or 91 
appropriate isotype controls.  After washing, intracellular staining for viral 92 
nucleoprotein (NP)-1, was performed using BD Cytofix/Cytoperm kit according to 93 
manufacturer’s instructions, and AlexaFluor 488 (AF488)-conjugated anti-NP1 94 
antibody (HB-65, a kind gift of 3VBiosciences).   95 
Flow cytometric analysis was performed on a FACSAria using FACSDiva 96 
software v5.0.3 (all BD).   97 
 98 
ELISpot 99 
Monocyte-depleted PBMC were defrosted at room temperature and suspended in 100 
RS RPMI.  MDMs were removed from 24-well culture plate using non-enzymatic cell 101 
dissociation solution (Sigma) and transferred to sterile 1.5 ml Eppendorf tubes.  Cells 102 
were centrifuged at 400 g, 4ºC, 5 min before resuspension in serum-free (SF) RPMI 103 
containing L-glutamine, penicillin/streptomycin, and fungizone.  MDMs were either 104 
not infected, or were treated with 2.5 x 104 pfu/ml X31 Influenza A H3N2 virus at 105 
37ºC for 2 h before washing and resuspending in RS RPMI.     106 
ELISpot for Human IFN-γ was then performed using 0.45 µm MultiScreen-IP 107 
Filter Plates (Millipore, Watford, UK) following manufacturer’s instructions (MabTech, 108 
Page 44 of 56 AJRCCM Articles in Press. Published on 30-October-2015 as 10.1164/rccm.201504-0782OC 
 Copyright © 2015 by the American Thoracic Society 
6 
 
Stockholm, Sweden).  Briefly, coating antibody (1-DIK) was diluted to 15 µg/ml in 109 
sterile DPBS and was added to the plate before overnight incubation at 4ºC. Plates 110 
were then washed five times with sterile DPBS before replacement with SF RPMI for 111 
30 min at RT.  The SF-media was then removed and MDM were added to each well 112 
at a concentration of 5 x 104 cells/well and 2.5 x 105 monocyte-depleted PBMC or 1 x 113 
105 CD8+ T cells were added to MDM-containing wells and incubated at 37ºC.  After 114 
22 h, the plate was washed five times with sterile DPBS + 0.05% Tween20 (Sigma).  115 
Detection antibody (7-B6-biotin) was diluted to 1 µg/ml in sterile DPBS + 0.5% FBS 116 
and was added to the plate which was then incubated at RT.  After 2 h, the plate was 117 
washed five times with sterile DPBS before addition of Streptavidin-ALP (diluted 118 
1:1000 in sterile DPBS+0.5% FCS) and incubation for 1 h at RT.  Plates were then 119 
washed with sterile DPBS before replacement with substrate solution (BCIP/NBT 120 
diluted 1:1:8 in sterile H2O). Plate was incubated at RT for 2-5m until clear spots 121 
were visible. At this point wells were washed five times with dH2O and allowed to dry 122 
at RT. Spot development was analysed using an AID EliSpot Reader (Germany) and 123 
AID EliSpot Software (Germany). 124 
In initial experiments, no IFNγ staining was seen in wells containing infected 125 
MDM or lymphocytes alone (1).  Peripheral blood T cells do not appear to be 126 
infected when exposed to X31 (1). 127 
 128 
RNA Isolation & RT-PCR 129 
RNA was extracted from T cells using a Stratagene Microprep Kit (Agilent 130 
Technologies, Stockport, UK).  Reverse transcription was carried out using a High 131 
Capacity cDNA Reverse Transcription Kit (Life Technologies) with random hexamers 132 
carried out according to the manufacturer’s protocols.  TIM3 gene expression was 133 
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analysed using TaqMan universal PCR master mix, No AmpErase® UNG in a 134 
7900HT fast real-time PCR system machine (all Life Technologies).  Gene 135 
expression was normalized to β2-microglobulin gene expression and quantified using 136 
the ∆∆ CT method. 137 
 138 
Supernatant analyses 139 
IFNβ concentrations in culture supernatants were measured by ELISA according to 140 
the manufacturer’s instructions (MSD, Gaithersberg, USA).  Culture supernatants 141 
were analysed by Luminex assay for IFNγ as per manufacturer’s instructions (Bio-142 
Rad, Hemel Hempstead, UK). 143 
 144 
Statistics 145 
Analysis of two groups was performed using Wilcoxon’s signed rank test for paired 146 
data and a Mann-Whitney U test for unpaired data. Chi-squared test and Fishers 147 
exact test were used for categorical data (GraphPad Prism v6, GraphPad Software 148 
Inc., San Diego, USA).  Results were considered significant if p<0.05.  149 
  150 
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Results 151 
 152 
 Control COPD p Value 
N 20 24 - 
Age (years) 
68 
(60.25 – 74.75) 
67 
(59.75 - 74) 
0.89# 
Gender M/F 9 / 11 12 / 12 0.741† 
BMI  
28 
(24.55 – 32.1) 
23.85 
(21.45 – 27.7) 
0.08# 
Confirmed 
corticosteroid use 
1 7 0.0544‡ 
Smoker 
(Never/Ex/Current) 
5 / 11 / 4 1 / 16 / 7  0.13‡ 
Pack Years 
20 
(0.9 – 55.25) 
40 
(29 – 56.25) 
0.11# 
FEV1% 
95 
(85.45 – 112.2) 
76.1 
(64.56 – 88.88) 
< 0.001# 
FEV1/FVC ratio 
0.752 
(0.727 – 0.8074) 
0.612 
(0.524 – 0.668) 
< 0.0001# 
Supplementary Table 1: Clinical characteristics of surgical patients shown in Figure 1 153 
B+C. Data are presented as median and IQR shown. Ex-smokers were defined as 154 
individuals who had stopped smoking for > 6 months prior to surgery. BMI data 155 
shown represents 13 Control and 16 COPD patients. #Mann Whitney U Test, †Chi-156 
squared test, ‡ Fishers Exact test 157 
 158 
 159 
 Control COPD p Value 
N 10 14 - 
Age (years) 
70.5 
(58.75 – 76.5) 
67 
(61.25 – 72.25) 
0.627# 
Gender M/F 4 / 6 6 / 8 1.00† 
BMI 
22.4 
(21.7 – 28.9) 
28.3 
(22.6 – 36.4) 
0.9# 
Confirmed 
corticosteroid use 
1 4 0.3577‡ 
Smoker 
(Never/Ex/Current) 
2 / 7 / 1 0 / 8 / 6  0.065# 
Pack Years 
40 
(1.5 – 56) 
40 
(34.38 – 66.25) 
0.35# 
FEV1% 
98 
(93 – 114) 
73 
(62 – 78.5) 
< 0.001# 
FEV1/FVC ratio 
0.747 
(0.747 – 0.797) 
0.605 
(0.523 – 0.642) 
< 0.0001# 
Supplementary Table 2: Clinical characteristics of surgical patients shown in Figures 160 
2-5. Data are presented as Median and IQR shown. Ex-smokers were defined as 161 
individuals who had stopped smoking for > 6 months prior to surgery. BMI data 162 
shown represents 3 Control and 5 COPD patients. #Mann Whitney U Test, †Chi-163 
squared test, ‡ Fishers Exact test 164 
  165 
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Control (24) COPD (33) 
24   Lung cancer 
2     Hypertension 
2     Hypercholesterolaemia 
2     Arthritis 
1     Hypothyroidism 
2     Hysterectomy 
1     Hip replacement 
2     Appendectomy 
1     Abdominal aortic aneurysm 
1     Varicose veins 
1     Irritable Bowel Syndrome 
1     Throat polyps 
1     Skin cancer 
2     Type 2 Diabetes 
33   Lung cancer 
5     Hypertension 
4     Hypercholesterolaemia 
4     Arthritis 
3     Hypothyroidism 
3     Hysterectomy 
2     Hip replacement 
1     Appendectomy 
1     Abdominal aortic aneurysm 
1     Varicose veins 
1     Irritable Bowel Syndrome 
1     Throat polyps 
1     Skin cancer 
1     Type 1 Diabetes 
Supplementary Table 3: Common comorbidities of surgical patients.  Number 166 
indicates incidence in each group.  Numbers do not sum as each patient can have 167 
more than one co-morbidity. 168 
  169 
Page 48 of 56 AJRCCM Articles in Press. Published on 30-October-2015 as 10.1164/rccm.201504-0782OC 
 Copyright © 2015 by the American Thoracic Society 
10 
 
Supplementary Figure Legends 170 
 171 
Supplementary Figure E1. CD4+ and CD8+ T cell population in human lung 172 
parenchymal tissue, Unstained singlet population was obtained from digested 173 
tissue. Dead cells were excluded using LIVE/DEAD® Fixable Aqua Dead Cell Stain. 174 
Live singlet CD45+ population was then identified and from this a CD45+CD3+ T cell 175 
population. The CD45+CD3+ T cell population was divided into CD4+ and CD8+ T 176 
cells. (A) Control samples (B) and COPD samples displaying their paired T cell 177 
populations. Control n = 20, COPD n = 24. 178 
 179 
Supplementary Figure E2. Flow cytometry gating strategy for memory CD4+ 180 
and CD8+ T cells. Naïve and Tmem cell populations in blood and tissue. 181 
PBMCs were isolated from blood using Ficoll-Paque density centrifugation. Tissue 182 
was prepared as previously described and digested in 0.5 mg/ml collagenase 183 
solution for 15 min. (A+C) T cell populations were gated on a singlet 184 
CD3+CD4+CD8- population or (B+D) a singlet CD3+CD4-CD8+ population. (A) 185 
CD4+ memory populations and (B) CD8+ populations in blood. (C) CD4+ memory 186 
populations and (D) CD8+ populations in lung parenchymal tissue.  Flow cytometry 187 
dot plots representative of at least 5 independent experiments. 188 
 189 
Supplementary Figure E3. RT-PCR gene expression of TIM-3 by T cells isolated 190 
from lung tissue. T cells were gated on the live CD45+CD3+ population. (A) RT-191 
PCR was performed with 2.5 x 104 CD4+ (B) or CD8+ T cells sorted from control or 192 
COPD lung parenchyma. ∆∆Ct value calculated using B2M housekeeping gene 193 
expression. n = 6 194 
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 195 
Supplementary Figure E4. Proportion of CD4+ and CD8+ T cells which express 196 
PD-1 in response to tissue infection by X31 influenza. (A) Proportion of CD4+ (B) 197 
and CD8+ T cells which expressed PD-1 was quantified by flow cytometry in non-198 
infected (NI), live X31 virus infection (X31) and UV-irradiated virus (UVX31) lung 199 
samples. (C) The fold increase in PD-1 expression (sMFI) of CD4+ (D) and CD8+ T 200 
cells between NI and X31-infected samples and NI and UVX31 (UV)- treated 201 
samples from COPD patients (n=12).  (E) The fold increase in PD-1 expression 202 
(sMFI) of CD4+ (F) and CD8+ T cells between NI and X31 samples was also 203 
calculated for Control samples (n = 9) and COPD samples (n = 12). Median and IQR 204 
shown, Data analysed using a Wilcoxon-signed rank test * p<0.05, ** p<0.01. 205 
 206 
Supplementary Figure E5. PD-L1 expression by epithelial cells during X31 207 
infection of lung parenchyma. 1cm3 sections of tissue were treated with UVX31, 208 
X31 or NI for 2 h before a 22 h incubation. Proportions of epithelial cells expressing 209 
PD-1 was quantified by flow cytometry. Control n = 9, COPD n = 11. Median and 210 
IQR shown. 211 
 212 
  213 
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